Guidant shareholders have overwhelmingly approved the agreement whereby Johnson & Johnson will acquire Guidant for $76 per share or $25.4 billion in fully diluted equity. The agreement remains subject to European and US regulatory review, as well as other customary closing conditions.
Ronald W Dollens, President and CEO, Guidant Corporation, commented, "We firmly believe this business combination offers an unprecedented breadth of capabilities and resources that will accelerate the growth of new therapies and technologies, benefiting millions of patients around the world."
|
